Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2018 from OUS - Section for urological oncology

9 publications found

Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L, Investigators of the Scandinavian Prostate Cancer Study Number 12 (2018)
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
Eur Urol, 73 (6), 870-876
DOI 10.1016/j.eururo.2018.01.012, PubMed 29395502

Ávila M, Patel L, López S, Cortés-Sanabria L, Garin O, Pont À, Ferrer F, Boladeras A, Zamora V, Fosså S, Storås AH, Sanda M, Serra-Sutton V, Ferrer M (2018)
Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis
Cancer Treat Rev, 66, 23-44
DOI 10.1016/j.ctrv.2018.03.005, PubMed 29673922

Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W (2018)
Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Urol Oncol, 37 (4), 289.e19-289.e26
DOI 10.1016/j.urolonc.2018.09.016, PubMed 30446451

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV et al. (2018)
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer
JAMA, 319 (9), 896-905
DOI 10.1001/jama.2018.0587, PubMed 29509865

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM et al. (2018)
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
Int J Radiat Oncol Biol Phys, 101 (4), 883-888
DOI 10.1016/j.ijrobp.2018.03.060, PubMed 29976500

Stranne J, Brasso K, Brennhovd B, Johansson E, Jäderling F, Kouri M, Lilleby W, Meidahl Petersen P, Mirtti T, Pettersson A, Rannikko A, Thellenberg C, Akre O (2018)
SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
Scand J Urol, 52 (5-6), 313-320
DOI 10.1080/21681805.2018.1520295, PubMed 30585526

Tulipan AJ, Hole KH, Vlatkovic L, Revheim ME, Reijnen JS, Willoch F, Seierstad T, Lilleby W (2018)
Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard
Acta Radiol, 60 (8), 1028-1038
DOI 10.1177/0284185118810977, PubMed 30379559

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W (2018)
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol, 132, 211-217
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241

Yachnin J, Gilje B, Thon K, Johansson H, Brandberg Y, Panaretakis T, Ullén A (2018)
Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab)
Eur J Cancer, 97, 33-40
DOI 10.1016/j.ejca.2018.03.007, PubMed 29685343

 
Page visits: 221249